ANBIO BIOTECHNOLOGY LTD (NNNN) Stock Fundamental Analysis
USA - NASDAQ:NNNN - KYG0367B1059 - Common Stock
29.38 USD
+1.81 (+6.57%)
NNNN gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 533 industry peers in the Biotechnology industry. Both the health and profitability get an excellent rating, making NNNN a very profitable company, without any liquidiy or solvency issues. NNNN is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year NNNN was profitable.
NNNN had a positive operating cash flow in the past year.
1.2 Ratios
NNNN has a better Return On Assets (31.55%) than 98.31% of its industry peers.
The Return On Equity of NNNN (34.72%) is better than 97.75% of its industry peers.
The Return On Invested Capital of NNNN (25.70%) is better than 98.31% of its industry peers.
The Average Return On Invested Capital over the past 3 years for NNNN is significantly above the industry average of 19.19%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 31.55% | ||
| ROE | 34.72% | ||
| ROIC | 25.71% |
ROA(3y)32.84%
ROA(5y)N/A
ROE(3y)36.27%
ROE(5y)N/A
ROIC(3y)27.94%
ROIC(5y)N/A
1.3 Margins
NNNN's Profit Margin of 42.53% is amongst the best of the industry. NNNN outperforms 98.12% of its industry peers.
NNNN's Profit Margin has declined in the last couple of years.
NNNN has a Operating Margin of 39.86%. This is amongst the best in the industry. NNNN outperforms 98.50% of its industry peers.
In the last couple of years the Operating Margin of NNNN has declined.
NNNN has a better Gross Margin (69.80%) than 81.05% of its industry peers.
In the last couple of years the Gross Margin of NNNN has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 39.86% | ||
| PM (TTM) | 42.53% | ||
| GM | 69.8% |
OM growth 3Y-23.96%
OM growth 5YN/A
PM growth 3Y-20.3%
PM growth 5YN/A
GM growth 3Y7.8%
GM growth 5YN/A
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so NNNN is creating value.
Compared to 1 year ago, NNNN has about the same amount of shares outstanding.
NNNN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
NNNN has an Altman-Z score of 423.67. This indicates that NNNN is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 423.67, NNNN belongs to the top of the industry, outperforming 99.81% of the companies in the same industry.
NNNN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 423.67 |
ROIC/WACC3.51
WACC7.33%
2.3 Liquidity
A Current Ratio of 10.71 indicates that NNNN has no problem at all paying its short term obligations.
With an excellent Current ratio value of 10.71, NNNN belongs to the best of the industry, outperforming 83.86% of the companies in the same industry.
A Quick Ratio of 10.71 indicates that NNNN has no problem at all paying its short term obligations.
NNNN has a Quick ratio of 10.71. This is amongst the best in the industry. NNNN outperforms 83.86% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 10.71 | ||
| Quick Ratio | 10.71 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 57.95% over the past year.
The Earnings Per Share has been decreasing by -2.10% on average over the past years.
Looking at the last year, NNNN shows a very strong growth in Revenue. The Revenue has grown by 43.63%.
Measured over the past years, NNNN shows a very strong growth in Revenue. The Revenue has been growing by 22.72% on average per year.
EPS 1Y (TTM)57.95%
EPS 3Y-2.1%
EPS 5YN/A
EPS Q2Q%6.37%
Revenue 1Y (TTM)43.63%
Revenue growth 3Y22.72%
Revenue growth 5YN/A
Sales Q2Q%21.95%
3.2 Future
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 734.50 indicates a quite expensive valuation of NNNN.
Compared to the rest of the industry, the Price/Earnings ratio of NNNN indicates a rather cheap valuation: NNNN is cheaper than 88.56% of the companies listed in the same industry.
NNNN is valuated expensively when we compare the Price/Earnings ratio to 25.47, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 734.5 | ||
| Fwd PE | N/A |
4.2 Price Multiples
Based on the Price/Free Cash Flow ratio, NNNN is valued cheaper than 89.49% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 619.83 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
The decent profitability rating of NNNN may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for NNNN!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:NNNN (11/20/2025, 11:00:11 AM)
29.38
+1.81 (+6.57%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners4.85%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap1.29B
Revenue(TTM)14.03M
Net Income(TTM)5.97M
AnalystsN/A
Price TargetN/A
Short Float %0.25%
Short Ratio1.93
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 734.5 | ||
| Fwd PE | N/A | ||
| P/S | 91.88 | ||
| P/FCF | 619.83 | ||
| P/OCF | 619.83 | ||
| P/B | 75.01 | ||
| P/tB | 75.01 | ||
| EV/EBITDA | N/A |
EPS(TTM)0.04
EY0.14%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)0.05
FCFY0.16%
OCF(TTM)0.05
OCFY0.16%
SpS0.32
BVpS0.39
TBVpS0.39
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0.59
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 31.55% | ||
| ROE | 34.72% | ||
| ROCE | 32.54% | ||
| ROIC | 25.71% | ||
| ROICexc | 81.37% | ||
| ROICexgc | 81.37% | ||
| OM | 39.86% | ||
| PM (TTM) | 42.53% | ||
| GM | 69.8% | ||
| FCFM | 14.82% |
ROA(3y)32.84%
ROA(5y)N/A
ROE(3y)36.27%
ROE(5y)N/A
ROIC(3y)27.94%
ROIC(5y)N/A
ROICexc(3y)88.97%
ROICexc(5y)N/A
ROICexgc(3y)88.97%
ROICexgc(5y)N/A
ROCE(3y)35.37%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y-23.96%
OM growth 5YN/A
PM growth 3Y-20.3%
PM growth 5YN/A
GM growth 3Y7.8%
GM growth 5YN/A
F-Score6
Asset Turnover0.74
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | 250 | ||
| Cash Conversion | N/A | ||
| Profit Quality | 34.85% | ||
| Current Ratio | 10.71 | ||
| Quick Ratio | 10.71 | ||
| Altman-Z | 423.67 |
F-Score6
WACC7.33%
ROIC/WACC3.51
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)57.33%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)57.95%
EPS 3Y-2.1%
EPS 5YN/A
EPS Q2Q%6.37%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)43.63%
Revenue growth 3Y22.72%
Revenue growth 5YN/A
Sales Q2Q%21.95%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y65.39%
EBIT growth 3Y-6.69%
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y131.57%
FCF growth 3Y-20.76%
FCF growth 5YN/A
OCF growth 1Y131.57%
OCF growth 3Y-20.76%
OCF growth 5YN/A
ANBIO BIOTECHNOLOGY LTD / NNNN FAQ
Can you provide the ChartMill fundamental rating for ANBIO BIOTECHNOLOGY LTD?
ChartMill assigns a fundamental rating of 6 / 10 to NNNN.
Can you provide the valuation status for ANBIO BIOTECHNOLOGY LTD?
ChartMill assigns a valuation rating of 3 / 10 to ANBIO BIOTECHNOLOGY LTD (NNNN). This can be considered as Overvalued.
Can you provide the profitability details for ANBIO BIOTECHNOLOGY LTD?
ANBIO BIOTECHNOLOGY LTD (NNNN) has a profitability rating of 7 / 10.